Let’s start up with the current stock price of Ginkgo Bioworks Holdings Inc. (DNA), which is $2.82 to be very precise. The Stock rose vividly during the last session to $3.19 after opening rate of $2.95 while the lowest price it went was recorded $2.855 before closing at $2.87.Recently in News on September 12, 2022, Renee Wegrzyn Slated to Lead New Advanced Research Projects Agency for Health. The White House today announced that President Biden intends to appoint Renee Wegrzyn, PhD, as the first Director of the Advanced Research Projects Agency for Health (ARPA-H). Dr. Wegrzyn is currently the Vice President for Business Development at Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming. ARPA-H was established in March 2022 to drive transformative health breakthroughs that cannot readily be accomplished through traditional research or commercial activity. You can read further details here
Ginkgo Bioworks Holdings Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $8.77 on 01/03/22, with the lowest value was $2.09 for the same time period, recorded on 05/12/22.
Ginkgo Bioworks Holdings Inc. (DNA) full year performance was -75.47%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Ginkgo Bioworks Holdings Inc. shares are logging -82.22% during the 52-week period from high price, and 34.93% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.09 and $15.86.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 11277968 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Ginkgo Bioworks Holdings Inc. (DNA) recorded performance in the market was -65.46%, having the revenues showcasing 15.26% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.77B, as it employees total of 641 workers.
Market experts do have their say about Ginkgo Bioworks Holdings Inc. (DNA)
During the last month, 0 analysts gave the Ginkgo Bioworks Holdings Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.90, with a change in the price was noted -0.07. In a similar fashion, Ginkgo Bioworks Holdings Inc. posted a movement of -2.41% for the period of last 100 days, recording 24,966,430 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for DNA is recording 0.03 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.03.
Technical breakdown of Ginkgo Bioworks Holdings Inc. (DNA)
Raw Stochastic average of Ginkgo Bioworks Holdings Inc. in the period of last 50 days is set at 18.75%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 45.71%. In the last 20 days, the company’s Stochastic %K was 50.48% and its Stochastic %D was recorded 56.83%.
Bearing in mind the latest performance of Ginkgo Bioworks Holdings Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -65.46%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -10.03%, alongside a downfall of -75.47% for the period of the last 12 months. The shares increased approximately by -6.51% in the 7-day charts and went down by 6.69% in the period of the last 30 days. Common stock shares were driven by 15.26% during last recorded quarter.